Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes
- PMID: 20462357
- DOI: 10.1086/652759
Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes
Abstract
Background: Drug-resistant Acinetobacter species are problematic in tertiary-care hospitals. We describe the epidemiology, resistance patterns, and outcomes of older adults with Acinetobacter infection in community hospitals.
Methods: We queried the microbiology databases of the Oakwood Healthcare System (4 hospitals with 632, 259, 199, and 168 beds) for clinical Acinetobacter cultures obtained in 2003-2008. Patients aged 60 years who were admitted from home or nursing homes were included. We recorded the initial Acinetobacter isolate and susceptibility to 8 antibiotics. Cultures obtained 48 h after hospitalization were categorized as "nosocomial." Administrative databases provided patients' origins (home or nursing home) and discharge destinations (home, nursing home, long-term acute-care facility, another hospital, or hospice care or death).
Results: During the 6-year period, 560 community-dwelling (mean age +/- standard deviation, 74 +/- 8.6 years) and 280 nursing home-dwelling (78 +/- 9.1 years) patients had Acinetobacter isolated. During this period, Acinetobacter prevalence increased 25% (P<.001, by trend test). In comparison of 2003 with 2008, Acinetobacter resistance to imipenem and ampicillin/sulbactam increased (from 1.8% to 33.1%; P<.001), as did "panresistance" (ie, resistance to all 8 antibiotics; increase from 0.0% to 13.6%; P<.001). Although resistance was stable in community-acquired isolates (resistance to approximately 4.2 antibiotics), resistance increased among nursing home-acquired and nosocomial-acquired isolates (from 4.5 to 5.7 and from 5.0 to 6.0 antibiotics, respectively; P<.01). At discharge, only 25% of community-dwelling and 50% of nursing home-dwelling patients returned to their place of origin; the remainder required higher levels of care or died. After adjustment for age, length of stay, and origin, resistance to each additional antibiotic predicted a >20% increased risk for discharge to higher levels of care or death (odds ratio, 1.23; 95% confidence interval, 1.11-1.36).
Conclusions: The prevalence and resistance of Acinetobacter species are increasing in the community. Patients with resistant isolates are selectively discharged to nursing homes and long-term acute-care facilities, introducing resistance to new facilities.
Comment in
-
The pivotal role of long-term care facilities in the epidemiology of Acinetobacter baumannii: another brick in the wall.Clin Infect Dis. 2010 Jun 15;50(12):1617-8. doi: 10.1086/652760. Clin Infect Dis. 2010. PMID: 20462356 No abstract available.
Similar articles
-
Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections.Int J Infect Dis. 2008 Jan;12(1):16-21. doi: 10.1016/j.ijid.2007.03.005. Epub 2007 May 21. Int J Infect Dis. 2008. PMID: 17513154
-
Emergence of resistant Acinetobacter baumannii in critically ill patients within an acute care teaching hospital and a long-term acute care hospital.Am J Infect Control. 2007 May;35(4):212-5. doi: 10.1016/j.ajic.2006.04.208. Am J Infect Control. 2007. PMID: 17482991
-
[Multidrug-resistant Acinetobacter baumannii infection in respiratory intensive care unit].Mikrobiyol Bul. 2009 Oct;43(4):575-85. Mikrobiyol Bul. 2009. PMID: 20084910 Turkish.
-
Acinetobacter baumannii: an emerging multidrug-resistant threat.Expert Rev Anti Infect Ther. 2008 Jun;6(3):309-25. doi: 10.1586/14787210.6.3.309. Expert Rev Anti Infect Ther. 2008. PMID: 18588496 Review.
-
Treatment of Acinetobacter infections.Expert Opin Pharmacother. 2010 Apr;11(5):779-88. doi: 10.1517/14656561003596350. Expert Opin Pharmacother. 2010. PMID: 20210684 Review.
Cited by
-
Prevalence of Acinetobacter baumannii and Candida auris in Patients Receiving Mechanical Ventilation.JAMA. 2023 Nov 14;330(18):1769-1772. doi: 10.1001/jama.2023.21083. JAMA. 2023. PMID: 37824710
-
Proteomic analysis of anti-MRSA activity of caerin 1.1/1.9 in a murine skin infection model and their in vitro anti-biofilm effects against Acinetobacter baumannii.Microbiol Spectr. 2023 Dec 12;11(6):e0452022. doi: 10.1128/spectrum.04520-22. Epub 2023 Oct 11. Microbiol Spectr. 2023. PMID: 37819110 Free PMC article.
-
Assesment of polyphenolic compounds against biofilms produced by clinical Acinetobacter baumannii strains using in silico and in vitro models.Saudi J Biol Sci. 2023 Sep;30(9):103743. doi: 10.1016/j.sjbs.2023.103743. Epub 2023 Jul 20. Saudi J Biol Sci. 2023. PMID: 37564783 Free PMC article.
-
Metabolomics revealed mechanism for the synergistic effect of sulbactam, polymyxin-B and amikacin combination against Acinetobacter baumannii.Front Microbiol. 2023 Jun 29;14:1217270. doi: 10.3389/fmicb.2023.1217270. eCollection 2023. Front Microbiol. 2023. PMID: 37455727 Free PMC article.
-
Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.Clin Infect Dis. 2023 May 1;76(Suppl 2):S194-S201. doi: 10.1093/cid/ciad095. Clin Infect Dis. 2023. PMID: 37125470 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
